SPECIAL FEATURE| Volume 356, ISSUE 4, P399-403, October 2018

Ischemic Stroke After Plasmapheresis


      Plasmapheresis involves the separation of all cellular elements of blood with the help of an extracorporeal semipermeable membrane. Even though plasmapheresis is generally considered safe, there have been anecdotal reports of thrombosis related to this exchange. We present 2 cases of healthy young males developing ischemic strokes within 24 hours of plasmapheresis. Patient A was a 24-year-old man with a family history of Factor V Leiden mutation presented with right-sided weakness 1 hour after donating plasma. A hypercoagulable work-up revealed elevations in Factor II. Patient B was a 42-year-old man who presented with a right facial droop, expressive aphasia and right arm weakness. He had donated plasma 18 hours before his presentation. A hypercoagulable work-up revealed elevated levels of von Willebrand factor antigen and high sensitivity C-reactive protein. A procoagulant state induced by plasmapheresis likely increases the risk for symptomatic thrombosis when an underlying thrombophilic state is present in the donor.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Ovali E, Ratip S, Ozmenoglu M, et al. Large volume donor plasmapheresis ininherited thrombophilia implicated in arterial thrombosis. Transfus Apher Sci. 2003;28(3):201-6.

      2. Leurent GBM, Camus C, Behar N, Mabo P. Can plasma donation induce coronary-artery thrombosis? J Blood Disord Transfus. 2010;1(103).

        • Nilsson T.
        • Rudolphi O.
        • Cedergren B.
        Effects of intensive plasmapheresis on the haemostatic system.
        Scand J Haematol. 1983; 30: 201-206
      3. Cross AR. Blood Donation Eligibility Requirements: The American Red Cross; Available from: Accessed August 27, 2016.

        • Press A.
        18 ed. Technical Manual. 120. Bethesda, MD: American Association of Blood Banks (AABB), 2014: 170
        • JW. S.
        Donation of red cells and plasma components by apheresis.
        in: McLeod BC P.T. Drew M.J. Apheresis: Principles and Practice. AABB Press, Bethesda, MD1997: 211-221
        • McLeod B.C.
        • Price T.H.
        • Owen H.
        • et al.
        Frequency of immediate adverse effects associated with apheresis donation.
        Transfusion. 1998; 38: 938-943
        • Crocco A.
        • D’Elia D.
        Adverse reactions during voluntary donation of blood and/or blood components. A statistical-epidemiological study.
        Blood Transfus. 2007; 5: 143-152
        • Climent-Peris C.
        • Velez-Rosario R.
        Immediate transfusion reactions.
        P R Health Sci J. 2001; 20: 229-235
        • Crocco I.
        • Franchini M.
        • Garozzo G.
        • et al.
        Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres.
        Blood Transfus. 2009; 7: 35-38
        • Press A.
        Apheresis: Principles and Practice. 3rd ed. American Association of Blood Banks (AABB), 2010: 211-221
        • Schmitt E.
        • Kundt G.
        • Klinkmann H.
        Three years with a national apheresis registry.
        J Clin Apher. 1992; 7: 58-62
        • Diekamp U G.J.
        • Rabe A.
        • Kießig S T.
        Donor hemovigilance during preparatory plasmapheresis.
        Transfus Med Hemother. 2014; 41: 123-133
        • Keller F.
        • Schultze G.
        • Offermann G.
        • et al.
        Complications during therapeutic plasma exchange.
        Acute Care. 1985; 11: 100-105
        • Boogaerts M.A.
        • Roelant C.
        • Goossens W.
        • et al.
        Complement activation and adult respiratory distress syndrome during intermittent flow apheresis procedures.
        Transfusion. 1986; 26: 82-87
        • Zimmermann B.
        • Scheel H.
        • Wegner H.
        Thrombophilia in blood-donation for plasma- and cytapheresis caused by antithrombin III depletion.
        Folia Haematol Int Mag Klin Morphol Blutforsch. 1988; 115: 314-318
      4. Rajbhandary SSJ, Land KJ, Whitaker BI (eds). AABB Donor Hemovigilance Report: 2012–2014 on behalf of the AABB US Donor Hemovigilance Working Group, 2016.

        • Rosencher J.
        • Zuily S.
        • Varenne O.
        • et al.
        Acute myocardial infarction secondary to platelet apheresis in a 57-year healthy donor.
        Int J Cardiol. 2011; 150: e119-e120
        • Ocak G.
        • Vossen C.Y.
        • Rotmans J.I.
        • et al.
        Venous and arterial thrombosis in dialysis patients.
        Thromb Haemost. 2011; 106: 1046-1052
        • Flaum MA C.R.
        • Appelbaum F.R.
        • et al.
        The hemostatic imbalance of plasma-exchange transfusion.
        Blood. 1979; 54: 694-702
        • Nilsson T R.O.
        • Cedergren B.
        Effects of intensive plasmapheresis on the haemostatic system.
        Scand J Haematol. 1983; 30: 201-206
        • Keswani S.C.
        • Chauhan N.
        Antiphospholipid syndrome.
        J R Soc Med. 2002; 95: 336-342
        • Halbmayer W.M.
        • Mannhalter C.
        • Feichtinger C.
        • et al.
        Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction.
        Wien Med Wochenschr. 1993; 143: 43-50
        • Lane D.A.
        • Grant P.J.
        Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.
        Blood. 2000; 95: 1517-1532
        • Giordano P.
        • De Lucia D.
        • Coppola B.
        • et al.
        Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report.
        Acta Haematol. 1999; 102 ( 101-103
        • Gallagher P.M.
        • Meleady R.
        • Shields D.C.
        • et al.
        Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation.
        Circulation. 1996; 94: 2154-2158
        • Zheng Y.Z.
        • Tong J.
        • Do X.P.
        • et al.
        Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population.
        Br J Haematol. 2000; 109: 870-874
        • Meade T.W.
        • Cooper J.A.
        • Stirling Y.
        • et al.
        Factor VIII, ABO blood group and the incidence of ischaemic heart disease.
        Br J Haematol. 1994; 88: 601-607
        • Folsom A.R.
        • Wu K.K.
        • Rosamond W.D.
        • et al.
        Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
        Circulation. 1997; 96: 1102-1108
        • Folsom A.R.
        • Rosamond W.D.
        • Shahar E.
        • et al.
        Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study investigators.
        Circulation. 1999; 100: 736-742
        • Sultan Y.
        • Bussel A.
        • Maisonneuve P.
        • et al.
        Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease.
        Transfusion. 1979; 19: 588-593
        • Wood L.
        • Jacobs P.
        The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels.
        J Clin Apheresis. 1986; 3: 124-128
        • Mannucci P.M.
        • D’Angelo A.
        • Vigano S.
        • et al.
        Decrease and rapid recovery of protein C after plasma exchange.
        Transfusion. 1986; 26: 156-158
        • Chirnside A.
        • Urbaniak S.J.
        • Prowse C.V.
        • et al.
        Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III.
        Br J Haematol. 1981; 48: 627-634
        • Wun T.
        • Paglieroni T.
        • Holland P.
        Prolonged circulation of activated platelets following plasmapheresis.
        J Clin Apher. 1994; 9: 10-16
        • Reimann P.M.
        • Mason P.D.
        Plasmapheresis: technique and complications.
        Intensive Care Med. 1990; 16: 3-10
        • Rinder C.S.
        • Bonan J.L.
        • Rinder H.M.
        • et al.
        Cardiopulmonary bypass induces leukocyte-platelet adhesion.
        Blood. 1992; 79: 1201-1205
        • Inbal A.
        • Freimark D.
        • Modan B.
        • et al.
        Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males.
        Blood. 1999; 93: 2186-2190
        • Miller G.J.
        • Bauer K.A.
        • Cooper J.A.
        • et al.
        Activation of the coagulant pathway in cigarette smokers.
        Thromb Haemost. 1998; 79: 549-553